Logotype for Ser Educacional SA

Ser Educacional (SEER3) Q4 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Ser Educacional SA

Q4 2024 earnings summary

19 May, 2026

Executive summary

  • Achieved strong double-digit growth in adjusted EBITDA and net operating cash generation, with adjusted EBITDA up 18.3% to R$122.5 million and net operating cash up 206.4% year-over-year, enabling a 9.3% reduction in net debt and resumption of dividend payments after three years.

  • Adjusted net income surged 101.3% to R$36.3 million in 4Q24, with margin expansion and improved leverage.

  • Operational optimization since 2022 has driven sustainable results, including margin expansion, improved cash flow, and reduced financial leverage for the eighth consecutive quarter.

  • Significant expansion in student base, especially in hybrid and health-related courses, with hybrid undergraduate intake up 16.7% and digital undergraduate intake up 9.2% year-over-year.

  • Dividend of R$19.6 million (R$0.15 per share) approved for May 2025, pending shareholder approval.

Financial highlights

  • Net revenue rose 8.7% year-over-year to R$523.8 million in 4Q24; full-year revenue up 8.2%.

  • Adjusted EBITDA increased 18.3% to R$122.5 million in 4Q24; margin expanded 1.9 p.p. to 23.4%.

  • Adjusted net income surged 101.3% to R$36.3 million in 4Q24; adjusted net margin up to 6.9%.

  • Net operating cash generation jumped 206.4% to R$50.1 million in 4Q24.

  • Net debt reduced by 9.3% to R$718.5 million; net debt/adjusted EBITDA improved from 2.17x to 1.64x.

Outlook and guidance

  • Entering 2025 with a larger number of medical student places, expected to be a key driver of future results.

  • Strategic focus on expanding medical schools and health-related courses, with disciplined expansion in high-demand areas and participation in Mais Médicos.

  • Continued focus on operational efficiency, cash generation, and further debt reduction, with plans for greater dividend distribution from 2026.

  • Ongoing operational optimization and portfolio reshaping to drive future growth and margin expansion.

  • New cycle of growth anticipated, supported by increased medical seats and new unit openings.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more